Genetics in the Effect of Caffeine on Fat Oxidation
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05975489 |
Recruitment Status :
Completed
First Posted : August 4, 2023
Last Update Posted : August 8, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Genetic Predisposition Caffeine Fat Burn | Dietary Supplement: Acute caffeine supplementation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 32 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Basic Science |
Official Title: | Influence of the Genetic Polymorphisms in the Effect of Caffeine on Fat Oxidation During Exercise |
Actual Study Start Date : | October 1, 2020 |
Actual Primary Completion Date : | February 10, 2021 |
Actual Study Completion Date : | April 1, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: Caffeine 3mg/kg intake
A dose of 3 mg/kg of caffeine (Bulk Powders, Essex, United Kingdom) was ingested before the beginning of each test.
|
Dietary Supplement: Acute caffeine supplementation
To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women |
Experimental: Caffeine 6mg/kg intake
A dose of 6 mg/kg of caffeine (Bulk Powders, Essex, United Kingdom) was ingested before the beginning of each test.
|
Dietary Supplement: Acute caffeine supplementation
To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women |
Placebo Comparator: Placebo intake
A dose of 3 mg/kg of placebo (Cellulose, Guinama, Valencia, Spain) was ingested before the beginning of each test.
|
Dietary Supplement: Acute caffeine supplementation
To evaluate the influence of the time of the day (i.e., morning vs evening) on the effect of caffeine on maximal fat oxidation in women |
- Genotype frequency of CYP1A2 polymorphism [ Time Frame: Baseline ]Samples shall be obtained by swabbing and scraping of the buccal mucosa by the participant. The c.-163A>C (rs762551) polymorphism will be used.
- Genotype frequency of GSTP polymorphism [ Time Frame: Baseline ]Samples shall be obtained by swabbing and scraping of the buccal mucosa by the participant. The c.1444G>A (rs8192678) and C>T (rs17650401) polymorphisms will be used.
- Genotype frequency of PGC1a polymorphisms [ Time Frame: Baseline ]Samples shall be obtained by swabbing and scraping of the buccal mucosa by the participant. The c.313A>G (rs1695) polymorphism will be used.
- FATmax [ Time Frame: 2-months ]The intensity of exercise that elicits MFO
- MFO [ Time Frame: 2-months ]Maximal fat oxidation during exercise
- RPE [ Time Frame: 2-months ]Rate of percevied exertion during exercise
- FAT and CHO oxidation [ Time Frame: 2-months ]Fat and carbohydrates oxidation
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 40 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
To be non-smokers. To have low caffeine intake (i.e., < 50 mg of caffeine per day in the previous 2 months) To show no previous history of cardiopulmonary diseases or having suffered musculoskeletal injuries in the previous 6 months.
Exclusion Criteria:
To have VO2max values below 40 ml/kg/min To be sedentary
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05975489
Spain | |
Universidad Francisco de Vitoria | |
Pozuelo De Alarcón, Madrid, Spain, 28223 |
Principal Investigator: | David Varillas Delgado | Universidad Francisco de Vitoria, crta Pozuelo-Majadahonda km 1.800 PC 28223, Madrid, Spain |
Responsible Party: | Universidad Francisco de Vitoria |
ClinicalTrials.gov Identifier: | NCT05975489 |
Other Study ID Numbers: |
UFV_genetic_caffeine |
First Posted: | August 4, 2023 Key Record Dates |
Last Update Posted: | August 8, 2023 |
Last Verified: | July 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Genetic Predisposition to Disease Disease Susceptibility Disease Attributes Pathologic Processes Caffeine Central Nervous System Stimulants Physiological Effects of Drugs |
Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Purinergic P1 Receptor Antagonists Purinergic Antagonists Purinergic Agents Neurotransmitter Agents |